Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (NCT07310563) titled 'A Trial to Evaluate Interactions Between Antiemetic Medication and AMG 133 in Participants Living With Overweight or Obesity' on Dec. 16, 2025.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Basic Science. Masking: None (Open Label).
Primary Sponsor: Amgen
Condition:
Overweight
Obesity
Intervention:
Drug: AMG 133
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: December 10, 2024
Target Sample Size: 59
Countries of Recruitment:
United States
To know more, visit https://clinicaltrials.gov/study/NCT0731...